From Data to Discovery: How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning
Scientific knowledge is expanding faster than at any point in human history, with PubMed indexing over 1.3 million new biomedical …
From Our Partners
Chemistry CROs at a Crossroads: How SpiroChem Is Adapting to Market Shifts in 2025 and Beyond
As we approach 2025, the role of chemistry Contract Research Organizations (CROs) is undergoing profound transformation. Chemistry is no longer …
AI Is Key to Democratizing Drug Discovery
The global drug development landscape is bustling, with over 20,000 biotechs competing for investor attention. Now more than ever, having …
Beyond Traditional Clinical Trials: MEDSIR’s Adaptive Designs and Precision Medicine in Oncology
MEDSIR (Medica Scientia Innovation Research) is an international company, based in Barcelona and New Jersey, specializing in the design and …
Unlocking Interoperability with AI: How This Company is Building a New Framework for Clinical Trials
In an industry as critical as clinical trials, where efficient data management and swift processes are paramount, outdated tech methods …
How AI Empowers Biomarker-Driven Clinical Trials
Clinical trials are the lifeline of modern medicine, bridging the gap between lab-borne scientific discoveries and the availability of life-saving …
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often …
Revolutionizing Clinical Trials: How AI and Automation Reduced Study Build Time from Months to Days
In the realm of clinical trials, efficient data management and monitoring are crucial yet often hampered by outdated and time-consuming …
AI Becomes a Drop-in Replacement for Docking
The field of AI ligand pose prediction in the protein binding pockets (aka “AI docking”) witnessed unprecedented development in the …
This AI Startup Joins Forces With NVIDIA's BioNeMo to Boost Drug Discovery
Receptor.AI, a London-based drug discovery company and NVIDIA Inception member, has successfully integrated NVIDIA BioNeMo cloud APIs with their end-to-end …
Navigating the Crossroads of AI and Oncology: A Deep Dive with Lantern Pharma's CEO, Panna Sharma
The development of oncology drugs faces significant challenges, including a high failure rate (97%) in clinical trials, due to complex …
Busting the PoseBusters v3: AI Docking Software ArtiDock Beats Industry’s State of the Art in Speed and Accuracy
We at Receptor.AI are excited to present the next important milestone in the development of our next-generation AI docking model, …